Celcuity secures up to $180M debt financing, plans Phase 3 gedatolisib trial in HR+/HER2- breast cancer

Celcuity Inc.

New A&R Loan Agreement with Innovatus and Oxford provides up to $180M; $100M funded including $61.7M new borrowings.
Loan matures May 2029; interest-only for 36 months (extendable to 48 months) at Prime + 2.85% (floor 7.75%).
Phase 3 VIKTORIA-2 trial to enroll ~638 HR+/HER2- ABC patients; first patient expected Q2 2025.
Trial design allows investigator choice of ribociclib or palbociclib; FDA concurred in Type C meeting.
Warrants issued equal to 2.5% of each tranche; Innovatus can convert up to 20% of Term A at $10.00/share.

item 1.01 item 8.01 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.